---
title: "Pasithea Therapeutics Corp. (KTTA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KTTA.US.md"
symbol: "KTTA.US"
name: "Pasithea Therapeutics Corp."
industry: "Biotechnology"
datetime: "2026-05-20T12:37:53.580Z"
locales:
  - [en](https://longbridge.com/en/quote/KTTA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KTTA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KTTA.US.md)
---

# Pasithea Therapeutics Corp. (KTTA.US)

## Company Overview

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.pasithea.com](https://www.pasithea.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.89 | 174 | - | - | - |
| PB | 0.32 | 18 | 1.56 | 0.41 | 0.35 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-20T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.70 |
| Highest Target | 3.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KTTA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KTTA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KTTA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KTTA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**